<?xml version="1.0" encoding="UTF-8"?>
<fig id="cancers-12-00713-f005" orientation="portrait" position="float">
 <label>Figure 5</label>
 <caption>
  <p>Pharmacological activation of SAMHD1 enhances cytotoxicity of antimetabolites. (
   <bold>A</bold>–
   <bold>C</bold>) Effect on cell viability of palbociclib–pemetrexed combination in TZM-bl, T47D and MDA-MB-468 cell lines, respectively. Left panels, cytotoxic activity of palbociclib alone (5 µM, white bars), pemetrexed alone (black bars at 0.2, 1 or 0.04 µM for TZM-bl, T47D and MDA-MB-468 respectively) or the combination of both drugs at the same concentration (grey bars). Right panels, cytotoxic activity of palbociclib alone (5 µM, white bars), fluorouracil alone (5 µM, black bars) or the combination of both drugs at the same concentration (grey bars). Drug concentrations were chosen depending calculated CC
   <sub>50</sub> under specific experimental conditions (
   <xref ref-type="app" rid="app1-cancers-12-00713">Table S1</xref>). * 
   <italic>p</italic> &lt; 0.05; ** 
   <italic>p</italic> &lt; 0.005; *** 
   <italic>p</italic> &lt; 0.0005. PD, palbociclib; PTX, pemetrexed; FU, 5-fluorouracil.
  </p>
 </caption>
 <graphic xlink:href="cancers-12-00713-g005" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</fig>
